Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Journal
The Lancet
Journal Volume
389
Journal Issue
10086
Pages
2317-2327
Date Issued
2017
Author(s)
Nash P.
Kirkham B.
Okada M.
Rahman P.
Combe B.
Burmester G.-R.
Adams D.H.
Kerr L.
Lee C.
Shuler C.L.
Genovese M.
Ahmed K.
Alper J.
Barkham N.
Bennett R.E.
Garc?a F.J.B.
Alonso R.B.
Blumstein H.B.
Brooks M.S.
Burmester G.-R.
Cagnoli P.
Caldron P.H.
Cantagrel A.
Chen D.-Y.
Churchill M.A.
Jr, Codding C.E.
Combe B.
Deane P.M.G.
Del Giudice J.
Deodhar A.A.
Dhar R.K.
Dokoupilova E.
Egan R.M.
Everding A.
Gal?ndez E.
Genovese M.
Goddard D.H.
Gottlieb A.
Goupille P.
Griffin R.M.
Gupta R.C.
Hall S.
Hatti K.
Howell M.P.
Huang Y.-H.
Jajoo R.
Janssen N.M.
Kiltz U.
Kivitz A.J.
Klein S.J.
Korkosz M.P.
Kotha R.
Kremer J.M.
Lue C.
de la Fuente J.L.M.
Marzo-Ortega H.
Masmitja J.G.
Mease P.J.
Meroni P.L.
Mueller E.C.
Nandagudi A.C.
Nash P.
Fern?ndez-Nebro A.
Neuwelt C.M.
Orbai A.M.
Oza M.R.
Parks D.L.
Pattanaik D.
Rell-Bakalarska M.E.
Rosmarin D.
Roussou E.
Rychlewska-Hanczewksa A.I.
Sikes D.H.
Stack M.T.
Sunkureddi P.
Tahir H.
Tha?i D.
Turkiewicz A.M.
Unger L.
Cabello R.V.
Wagner U.
Wei C.-C.
Wells A.F.
Youssef P.
Zielinska A.
Publisher
Lancet Publishing Group
Type
journal article